Phospho-PIK3R1/PIK3R3 (Tyr467/199) Antibody

What is the PI3K signaling pathway and what role does PIK3R1/PIK3R3 phosphorylation play?

The PI3K (Phosphatidylinositol 3-kinase) signaling pathway is a critical cellular mechanism essential for regulating cell growth, proliferation, and survival. Dysregulation of this pathway is implicated in various diseases, including cancer, metabolic disorders, and inflammatory conditions .

PIK3R1 and PIK3R3 are regulatory subunits of the PI3K enzyme complex. Specifically, PIK3R1 encodes the p85α regulatory subunit that forms heterodimers with catalytic subunits (such as p110α, p110β, or p110δ). Phosphorylation at tyrosine residues 467 on PIK3R1 and 199 on PIK3R3 represents key regulatory events in the activation of the PI3K complex. These phosphorylation events can alter the interaction between regulatory and catalytic subunits, thereby modulating downstream signaling events such as AKT phosphorylation and activation .

The phosphorylation status of these regulatory subunits provides critical insights into the activation state of the PI3K pathway, making antibodies specific to these phosphorylation sites valuable tools for studying pathway dynamics and regulation.

What applications is the Phospho-PIK3R1/PIK3R3 (Tyr467/199) Antibody validated for?

The Phospho-PIK3R1/PIK3R3 (Tyr467/199) Antibody has been validated for multiple research applications, providing researchers with versatility in experimental approaches:

The antibody demonstrates highest validation for Western blot applications, making it particularly useful for analyzing phosphorylation status in cell and tissue lysates following various experimental treatments or in disease models. For optimal results in each application, researchers should perform dilution optimization experiments with appropriate positive and negative controls .

What species reactivity does the Phospho-PIK3R1/PIK3R3 (Tyr467/199) Antibody display?

The Phospho-PIK3R1/PIK3R3 (Tyr467/199) Antibody demonstrates cross-reactivity with multiple species, making it versatile for comparative studies across different model systems:

This broad species reactivity can be attributed to the high conservation of the phosphorylation sites and surrounding amino acid sequences across these species. Researchers should note that despite this cross-reactivity, validation experiments should still be performed when using this antibody in species not explicitly tested by the manufacturer .

What are the implications of PIK3R1 mutations on AKT activation and p110 protein levels?

Studies on PIK3R1 mutations provide crucial insights into disease mechanisms, particularly for Activated PI3K Delta Syndrome 2 (APDS2) and SHORT syndrome. Research findings demonstrate complex effects on signaling:

Mutation Effects on Protein Interactions:

Recent research on PIK3R1(deltaExon11) mutation has revealed paradoxical dominant negative activity. This mutation results in:

• Reduced association with p110α catalytic subunit

• Enhanced interaction with Irs1/2 adapter proteins

• Decreased AKT phosphorylation and activation

• Reduced p110δ protein levels in patient-derived cells

Comparative Analysis of Different PIK3R1 Mutations:

These findings challenge the traditional view that mutations in regulatory subunits simply release inhibition of catalytic subunits. Instead, they suggest a competitive sequestration model where mutant regulatory subunits preferentially bind adapter proteins like Irs1/2, preventing normal signaling complex formation .

How does phosphorylation of PIK3R1 at Tyr467 influence its interaction with catalytic subunits?

The phosphorylation of PIK3R1 at Tyr467 represents a critical regulatory mechanism influencing the assembly and activity of the PI3K complex:

Molecular Mechanism:
Phosphorylation at Tyr467 occurs within the inter-SH2 (iSH2) domain of p85α (PIK3R1), which serves as the primary interface for interaction with the catalytic p110 subunits. This phosphorylation can modulate the binding affinity between regulatory and catalytic subunits, thereby affecting complex stability and enzymatic activity.

Signaling Consequences:

• Phosphorylation at Tyr467 can induce conformational changes in the p85α regulatory subunit

• These changes may relieve the inhibitory effects of p85α on p110 catalytic activity

• Enhanced PI3K lipid kinase activity leads to increased PIP3 production

• Downstream effectors like AKT become activated through PIP3-dependent mechanisms

Research has demonstrated that mutations affecting regions near this phosphorylation site (such as deltaExon11) can disrupt normal interaction patterns between p85α and p110, leading to altered signaling outcomes. For instance, the deltaExon11 mutation reduces association with p110α but enhances interaction with insulin receptor substrates (Irs1/2) .

What methodological approaches can distinguish between the effects of phosphorylation at PIK3R1 (Tyr467) versus PIK3R3 (Tyr199)?

Distinguishing between phosphorylation effects on PIK3R1 (Tyr467) and PIK3R3 (Tyr199) requires sophisticated experimental approaches:

Selective Knockdown Strategy:

• Use siRNA or shRNA to selectively knock down either PIK3R1 or PIK3R3

• Reconstitute with phosphomimetic (Y→D/E) or phosphodeficient (Y→F) mutants

• Assess downstream signaling effects through phosphorylation of AKT, S6K, and other effectors

Isoform-Specific Immunoprecipitation:

• Use isoform-specific antibodies against total PIK3R1 or PIK3R3

• Immunoprecipitate each isoform separately

• Probe with the phospho-specific antibody to determine relative phosphorylation levels

• Correlate with functional outcomes in the same experimental setting

Cell Type Considerations:
Different cell types express varying ratios of PIK3R1 versus PIK3R3, which can influence experimental results. For example:

These methodological considerations can help researchers design experiments that specifically address the distinct roles of phosphorylation at these homologous sites in the different regulatory subunits .

How should experimental controls be designed when studying PIK3R1/PIK3R3 phosphorylation?

Robust experimental design requires careful consideration of controls to ensure valid interpretation of results related to PIK3R1/PIK3R3 phosphorylation:

Positive Controls:

• Insulin stimulation (10-100 nM, 10-15 minutes) in responsive cell lines (e.g., 3T3-L1, HepG2)

• PDGF stimulation (50 ng/mL, 5-10 minutes) in fibroblasts or smooth muscle cells

• EGF stimulation (100 ng/mL, 5-10 minutes) in epithelial cell lines

Negative Controls:

• Serum-starved, unstimulated cells

• Phosphatase-treated lysates (λ-phosphatase incubation)

• PI3K inhibitor pre-treatment (e.g., wortmannin 100 nM or LY294002 10 μM)

Validation Controls:

• Antibody validation using phosphopeptide competition assays

• siRNA knockdown of PIK3R1/PIK3R3 to confirm signal specificity

• Phospho-deficient mutants (Y467F for PIK3R1, Y199F for PIK3R3)

Time-Course Experimental Design:
For optimal detection of phosphorylation dynamics, researchers should consider the following time points after stimulation:

This comprehensive control strategy ensures that observed changes in phosphorylation status can be attributed specifically to the experimental variables under investigation .

What are common pitfalls in phospho-PIK3R1/PIK3R3 detection and how can they be avoided?

Detecting phosphorylated forms of PIK3R1/PIK3R3 presents several technical challenges that researchers should anticipate and address:

Sample Preparation Pitfalls:

• Phosphatase Activity: Even brief exposure to phosphatases during sample preparation can dramatically reduce signal.
  Solution: Use fresh phosphatase inhibitor cocktails in all buffers and maintain samples at 4°C.

• Protein Degradation: Regulatory subunits may undergo proteolysis during extended handling.
  Solution: Add protease inhibitors and process samples quickly; avoid repeated freeze-thaw cycles.

• Stimulation Conditions: Insufficient or excessive stimulation can yield misleading results.
  Solution: Establish optimal stimulation conditions through time-course and dose-response experiments.

Technical Detection Issues:

• Antibody Cross-Reactivity: Some phospho-specific antibodies may recognize related phosphorylation sites.
  Solution: Validate specificity using phospho-deficient mutants (Y467F for PIK3R1, Y199F for PIK3R3).

• Background Signal: High background can mask specific signals, particularly in IHC/IF applications.
  Solution: Optimize blocking conditions and include peptide competition controls.

• Signal Quantification: Linear dynamic range limitations may affect quantitative comparisons.
  Solution: Use multiple exposure times and establish standard curves with recombinant phosphoproteins.

Troubleshooting Guide:

By anticipating these common pitfalls and implementing the suggested solutions, researchers can improve the reliability and reproducibility of their phospho-PIK3R1/PIK3R3 detection experiments .

How might research on PIK3R1/PIK3R3 phosphorylation contribute to understanding disease mechanisms?

The study of PIK3R1/PIK3R3 phosphorylation offers significant potential for elucidating disease mechanisms across multiple conditions:

Cancer Biology Applications:

• Phosphorylation status may serve as a biomarker for PI3K pathway activation in tumors

• Differential phosphorylation patterns could predict response to PI3K inhibitor therapies

• Mutations affecting phosphorylation sites may contribute to therapy resistance mechanisms

Immunological Disorder Insights:
Research on Activated PI3K Delta Syndrome (APDS) has demonstrated that PIK3R1 mutations (e.g., deltaExon11) can cause immunodeficiency through paradoxical inhibition of PI3K signaling. This challenges previous assumptions about activating mutations and suggests complex regulatory mechanisms govern immune cell function .

Metabolic Disease Mechanisms:
The strong interaction between mutant p85α and insulin receptor substrates (Irs1/2) observed in PIK3R1 mutants provides mechanistic insight into conditions like SHORT syndrome, characterized by insulin resistance. This dominant negative sequestration model explains how mutations in regulatory subunits can impair metabolic signaling without directly affecting catalytic activity .

Future Research Priorities:

• Development of phosphorylation site-specific monoclonal antibodies with enhanced specificity

• Global phosphoproteomic analysis of patient-derived cells with PIK3R1 mutations

• Structural biology studies of phosphorylation-induced conformational changes

• In vivo models expressing phosphomimetic or phosphodeficient mutants

• Integration of phosphorylation data with other post-translational modifications

These research directions will enhance our understanding of how phosphorylation of regulatory subunits contributes to normal physiology and disease pathogenesis, potentially leading to novel therapeutic approaches targeting these specific modifications .